Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study

INTRODUCTION: The blockade of interleukine-1 (anakinra and canakinumab) is a well-known highly effective tool for monogenic autoinflammatory diseases (AIDs), such as familial Mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome, hyperimmunoglobulinaemia D syndrome, and cr...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexeeva, Ekaterina, Shingarova, Meiri, Dvoryakovskaya, Tatyana, Lomakina, Olga, Fetisova, Anna, Isaeva, Ksenia, Chomakhidze, Aleksandra, Chibisova, Kristina, Krekhova, Elizaveta, Kozodaeva, Aleksandra, Savostyanov, Kirill, Pushkov, Aleksandr, Zhanin, Ilya, Demyanov, Dmitry, Suspitsin, Evgeny, Belozerov, Konstantin, Kostik, Mikhail
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685903/
https://www.ncbi.nlm.nih.gov/pubmed/38034538
http://dx.doi.org/10.3389/fmed.2023.1257045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685903/
https://www.ncbi.nlm.nih.gov/pubmed/38034538
http://dx.doi.org/10.3389/fmed.2023.1257045

Ejemplares similares